Radioligand therapy slows advanced PSMA+ prostate cancer

(HealthDay)—Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, according to a study published online June 23 in the New England Journal of Medicine. Oliver Sartor, M.D., from Tulane University in New Orleans, and colleagues conducted an…

Enhanced oral uptake of exosomes opens cell therapy alternative

Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows. The findings, published in the peer-reviewed Journal of Extracellular Vesicles, could help develop new oral medications for treating patients with muscular…

Safety evaluation of conditionally immortalized cells for renal replacement therapy

A research team assessed the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, by using in vitro assays and athymic nude rats. They demonstrate that these cells do not possess key properties of oncogenically transformed cells, including anchorage-independent growth, lack of contact inhibition and apoptosis-resistance. Taken…